Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCardiovascular

Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: A pharmacological appraisal

Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Giorgio Reggiardo
Journal of Pharmacology and Experimental Therapeutics November 9, 2020, JPET-AR-2020-000323; DOI: https://doi.org/10.1124/jpet.120.000323
Giorgio Minotti
1University Campus Bio-Medico of Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: g.minotti@unicampus.it
Pierantonio Menna
2Clinical Pharmacology, University Hospital Campus Bio-Medico of Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimiliano Camilli
3Catholic University of the Sacred Heart, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emanuela Salvatorelli
1University Campus Bio-Medico of Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giorgio Reggiardo
4Biostatistics and Data Management Unit, Mediservice S.r.l., Agrate Brianza, Monza, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Diastolic dysfunction (DD) is an early manifestation of cancer drugs cardiotoxicity. Anthracyclines are considered as more cardiotoxic than other chemotherapeutics but previous studies have shown that both anthracycline-based and nonanthracycline chemotherapy can cause an early DD, detected one week after the end of chemotherapy. Here we characterized if DD also occurred in a delayed form, detected six months after chemotherapy. Sixty-seven comorbidity-free patients were examined. DD was diagnosed by echocardiography and cardiac biomarkers. Early or delayed DD occurred in 26 or 13 patients, respectively, sharing a pattern of grade I DD (impaired relaxation at echocardiography) or elevated B-type natriuretic peptide. Binary logistic analysis showed that age, gender and type of chemotherapy (anthracycline-based versus nonanthracycline) did not independently increase the probability of early or delayed DD. Early DD was predicted by the patient's cardiovascular profile, and in particular by diastolic indices that were in ranges of normality but showed measurable discrepancies from mean control values. Delayed DD was not predicted by the patient's cardiovascular profile but was predicted by post-chemotherapy adjuvant treatments (e.g., chest radiation or hormone therapy). Early and delayed DD were accompanied my moderate LVEF decrements. These findings show that anthracycline-based and nonanthracycline chemotherapy can induce early or delayed DD, which are governed by different patient- or treatment- related factors. Pharmacologic interventions that prevent DD or mitigate its progression toward a more serious cardiac dysfunction should be considered.

Significance Statement Predictors of early or delayed diastolic dysfunction (DD) were investigated in cancer patients treated with anthracyline-based or nonanthracycline chemotherapy. The type of chemotherapy did not predict the risk of DD. Early DD was predicted by the patient’s cardiovascular profile. Delayed DD was predicted by the adjuvant treatments the patient received after chemotherapy. These findings show that any chemotherapeutic can cause DD; however, the trajectories of DD are differently influenced by patients’ characteristics or post-chemotherapy exposure to additional cardiotoxic hits.

  • Anti-cancer agents
  • cancer
  • cardiac toxicity
  • chemotherapy
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 376 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 376, Issue 3
1 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: A pharmacological appraisal
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCardiovascular

Chemotherapy and diastolic dysfunction

Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Giorgio Reggiardo
Journal of Pharmacology and Experimental Therapeutics November 9, 2020, JPET-AR-2020-000323; DOI: https://doi.org/10.1124/jpet.120.000323

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherCardiovascular

Chemotherapy and diastolic dysfunction

Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Giorgio Reggiardo
Journal of Pharmacology and Experimental Therapeutics November 9, 2020, JPET-AR-2020-000323; DOI: https://doi.org/10.1124/jpet.120.000323
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • β3-Agonist Improves Myocardial Stiffness
  • A Novel Inhibitor of Myocardial mPTP
  • Mast Cell Degranulation Enhances Big ET-1 Pressor Response
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics